Drug Combination Details
| General Information of the Combination (ID: C75431) | |||||
|---|---|---|---|---|---|
| Name | Physostigmine NP Info | + | Deprenyl Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Alzheimer disease
[ICD-11: 8A20]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Experimental
Result(s) |
Based on earlier positive findings in Alzheimer patients with the monoamine oxidase B inhibitor, 1-deprenyl, the authors speculate that a combination of physostigmine, the short-acting cholinesterase inhibitor, and 1-deprenyl might be more beneficial than either agent alone. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl. Int Psychogeriatr. 1992;4 Suppl 2:291-309. | |||
